Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.
2.

The use of antidepressants in clinical practice: focus on agomelatine.

McAllister-Williams RH, Baldwin DS, Haddad PM, Bazire S.

Hum Psychopharmacol. 2010 Mar;25(2):95-102. doi: 10.1002/hup.1094. Review.

PMID:
20196187
3.
4.

Antidepressant efficacy of agomelatine: meta-analysis of published and unpublished studies.

Taylor D, Sparshatt A, Varma S, Olofinjana O.

BMJ. 2014 Mar 19;348:g1888. doi: 10.1136/bmj.g1888. Review. Erratum in: BMJ. 2014;348:g2496.

5.

Superior antidepressant efficacy results of agomelatine versus fluoxetine in severe MDD patients: a randomized, double-blind study.

Hale A, Corral RM, Mencacci C, Ruiz JS, Severo CA, Gentil V.

Int Clin Psychopharmacol. 2010 Nov;25(6):305-14. doi: 10.1097/YIC.0b013e32833a86aa.

PMID:
20856123
6.

Efficacy of the novel antidepressant agomelatine on the circadian rest-activity cycle and depressive and anxiety symptoms in patients with major depressive disorder: a randomized, double-blind comparison with sertraline.

Kasper S, Hajak G, Wulff K, Hoogendijk WJ, Montejo AL, Smeraldi E, Rybakowski JK, Quera-Salva MA, Wirz-Justice AM, Picarel-Blanchot F, Baylé FJ.

J Clin Psychiatry. 2010 Feb;71(2):109-20. doi: 10.4088/JCP.09m05347blu.

PMID:
20193645
7.

Agomelatine in elderly--finally a patient friendly antidepressant in psychogeriatry?

Lužný J.

Actas Esp Psiquiatr. 2012 Nov-Dec;40(6):304-7. Epub 2012 Nov 1.

8.

Agomelatine: a review of adverse effects.

[No authors listed]

Prescrire Int. 2013 Mar;22(136):70-1.

PMID:
23593692
9.

Agomelatine: new drug. Adverse effects and no proven efficacy.

[No authors listed]

Prescrire Int. 2009 Dec;18(104):241-5.

PMID:
20020562
10.

Efficacy and tolerance profile of agomelatine and practical use in depressed patients.

Rouillon F.

Int Clin Psychopharmacol. 2006 Feb;21 Suppl 1:S31-5.

PMID:
16436938
11.

The antidepressant agomelatine improves the quality of life of depressed patients: implications for remission.

Llorca PM.

J Psychopharmacol. 2010 Aug;24(2 Suppl):21-6. doi: 10.1177/1359786810372978. Review.

PMID:
20663805
12.

Agomelatine and Transient Elevation of Creatine Phosphokinase.

Zormann A, Blum J, Suenderhauf C, Vogel M, Walter A.

Drug Res (Stuttg). 2016 Nov;66(11):614-616. Epub 2016 Aug 9.

PMID:
27504868
13.

The antidepressant agomelatine in daily practice: results of the non-interventional study VIVALDI.

Laux G; VIVALDI Study Group.

Pharmacopsychiatry. 2012 Nov;45(7):284-91. doi: 10.1055/s-0032-1309003. Epub 2012 May 16.

PMID:
22592503
14.

Melatonin receptor agonist agomelatine: a new drug for treating unipolar depression.

Bourin M, Prica C.

Curr Pharm Des. 2009;15(14):1675-82. Review.

PMID:
19442180
15.

Agomelatine: AGO 178, AGO178, S 20098.

[No authors listed]

Drugs R D. 2008;9(3):177-83.

PMID:
18457470
16.

Focus on agomelatine.

Green B.

Curr Med Res Opin. 2011 Apr;27(4):745-9. doi: 10.1185/03007995.2011.554534. Epub 2011 Jan 27. Review.

PMID:
21271795
17.

Beyond the monoaminergic hypothesis: agomelatine, a new antidepressant with an innovative mechanism of action.

Kasper S, Hamon M.

World J Biol Psychiatry. 2009;10(2):117-26. doi: 10.1080/15622970902717024. Review.

PMID:
19255935
18.

[QTc prolongation during treatment with agomelatine].

Kozian R, Syrbe G.

Psychiatr Prax. 2010 Nov;37(8):405-7. doi: 10.1055/s-0030-1248578. Epub 2010 Sep 16. German.

PMID:
20848378
19.

Agomelatine in the treatment of seasonal affective disorder.

Pjrek E, Winkler D, Konstantinidis A, Willeit M, Praschak-Rieder N, Kasper S.

Psychopharmacology (Berl). 2007 Mar;190(4):575-9. Epub 2006 Dec 15.

PMID:
17171557
20.

Supplemental Content

Support Center